

|   | FEASIBILITY | PRECLINICAL | CLINICAL | NDA FILING |
|---|-------------|-------------|----------|------------|
| <p><b>scFurosemide</b><br/><i>Diuresis at home instead of at hospital</i></p>   |             |             |          |            |
| <p>Furosemide is a well-known loop diuretic developed in the 1960s. It is one of the most widely used prescription pharmaceuticals in the United States. The use of intravenous furosemide is universally recommended in international guidelines for the management of edema in patients with decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. A novel, proprietary furosemide solution buffered to a neutral pH for subcutaneous administration via the sc2Wear® Furosemide Infusor, has been developed.</p> |             |             |          |            |
| <p><b>scCeftriaxone</b><br/><i>Cornerstone treatment for Gram<sup>+</sup> infections</i></p>  |             |             |          |            |
| <p>Ceftriaxone is an antibiotic currently used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.</p>   |             |             |          |            |
| <p><b>scCarbapenem</b><br/><i>Complement to scCeftriaxone for serious Gram<sup>-</sup> infections</i></p>   |             |             |          |            |
| <p>Carbapenems are antibiotics currently used intravenously for the treatment of infections caused by gram-negative organisms.</p>  |             |             |          |            |